New Assay Rapidly Detects Toxigenic C. difficile
By LabMedica International staff writers Posted on 01 Jul 2015 |
A new assay is available for simple, rapid detection of pathogenic Clostridium difficile in fecal samples using the CE-marked GenRead molecular diagnostics system.
C. difficile infection is rising at an accelerating rate, has become more severe and difficult to treat, and is now more common than healthcare-associated infections (HAIs) caused by methicillin-resistant Staphylococcus aureus (MRSA).
Orion Diagnostica Oy (Espoo, Finland) has launched Orion GenRead C. difficile kit, enabling fast and accurate detection directly from fecal samples. The test supports earlier treatment decisions by detecting strong positive samples in 15 minutes.
Orion GenRead tests are used on the GenRead instrument and are based on SIBA, Orion Diagnostica’s proprietary isothermal nucleic acid amplification technology. SIBA is a robust and highly specific technology that allows fast, continuous amplification of nucleic acids. The use of SIBA in assays combined with the Orion GenRead instrument and its intuitive user interface, enables C. difficile testing outside of traditional PCR laboratories. Together with the portable and easy-to-use GenRead instrument and the fast assay – testing is possible in a wide range of laboratories.
The CE-marked system, consisting of the instrument and the assay, is currently available through Orion Diagnostica’s dedicated distributor network in Europe.
Related Links:
Orion Diagnostica Oy
Orion GenRead system
C. difficile infection is rising at an accelerating rate, has become more severe and difficult to treat, and is now more common than healthcare-associated infections (HAIs) caused by methicillin-resistant Staphylococcus aureus (MRSA).
Orion Diagnostica Oy (Espoo, Finland) has launched Orion GenRead C. difficile kit, enabling fast and accurate detection directly from fecal samples. The test supports earlier treatment decisions by detecting strong positive samples in 15 minutes.
Orion GenRead tests are used on the GenRead instrument and are based on SIBA, Orion Diagnostica’s proprietary isothermal nucleic acid amplification technology. SIBA is a robust and highly specific technology that allows fast, continuous amplification of nucleic acids. The use of SIBA in assays combined with the Orion GenRead instrument and its intuitive user interface, enables C. difficile testing outside of traditional PCR laboratories. Together with the portable and easy-to-use GenRead instrument and the fast assay – testing is possible in a wide range of laboratories.
The CE-marked system, consisting of the instrument and the assay, is currently available through Orion Diagnostica’s dedicated distributor network in Europe.
Related Links:
Orion Diagnostica Oy
Orion GenRead system
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia